The Prime Minister's Economic Advisory Council has suggested a complex combination of three pricing models to fix retail prices of 348 Essential Drugs to balance industry's concerns and public health. The proposal, however, has drawn the ire of drug makers who say it is a watered down version of the health ministry's proposals. The council has proposed that for medicines facing "insufficient competition" or a monopoly-like situation, the retail price should...

-The Hindu   The Centre's move to introduce an experimental universal health package in at least one district per State under the National Rural Health Mission, with access to free generic drugs, is a welcome measure. But the larger mission to provide free essential medicines to all citizens need not await the results of such pilot studies. It should be rolled out for poor and non-poor alike quickly. There is no time...

The medicine price regulator, the National Pharmaceutical Pricing Authority (NPPA), has found a price fixing mechanism suggested by its parent ministry, chemicals and fertilisers, has failed to meaningfully lower the prices of key cancer medicines. A group of ministers (GoM) headed by agriculture minister Sharad Pawar is expected to meet soon to finalise a pricing policy on drugs. The NPPA study findings may compel the ministry to seek other effective ways of...

India's use of the compulsory licensing provision under its patents law for the first time to make the patented cancer drug Nexavar available at affordable prices is an essential, although belated step to curb the mounting cost of drugs. The grant of the licence by the Controller-General of Patents, Designs and Trade Marks to Natco Pharma for manufacture of the drug Sorafenib Tosylate (Nexavar) to treat liver and kidney cancer is...

A non-government organisation campaigning for cheaper Essential Drugs has proposed an alternative pricing model that seeks to fix retail prices at the average price of all brands in a segment.  The proposal of the All India Drug Action Network (AIDAN) is being examined by the department of pharmaceuticals (DoP), an official said. AIDAN says its new pricing mechanism, which excludes brands that account for the top 20% by sales, will make...